Protease-Resistant SDF-1 Peptide Mutants for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for wound healing and tissue repair are inadequate, particularly in conditions like diabetic ulcers and myocardial infarction, due to insufficient availability of stromal cell-derived factor-1 (SDF-1), which is essential for attracting progenitor cells and promoting tissue repair.
Innovation Solution
Development of protease-resistant mutants of SDF-1 peptides that maintain chemoattractant activity while being resistant to enzymes like MMP-2, MMP-9, and DPPIV, allowing for sustained delivery and enhanced tissue repair in damaged areas.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native SDF-1 is used for tissue repair, then chemoattractant activity is provided, but the peptide is rapidly inactivated by proteases
Solution Approach 1:
The patent applies parameter changes by systematically modifying the amino acid sequence of SDF-1 at specific positions (particularly N-terminal residues) to create mutant variants with altered protease susceptibility while preserving chemoattractant activity. This involves changing physical-chemical parameters of the peptide structure to achieve resistance against enzymatic degradation.
Solution Approach 2:
The patent creates simplified copy variants of SDF-1 by truncating the full-length peptide to shorter sequences (e.g., using only residues 1-7 or 1-8) that retain the essential chemoattractant function while being more resistant to proteolytic cleavage. These copied sequences serve as stable alternatives to the complete native peptide.
2Productivity
If SDF-1 is administered to promote wound healing, then tissue repair is enhanced, but the peptide undergoes enzymatic degradation
Solution Approach 1:
The patent modifies the peptide sequence parameters to reduce susceptibility to specific proteases (MMP-2, MMP-9, DPPIV, cathepsin G) while maintaining the biological function. This involves systematic substitution of amino acids at cleavage-prone positions to prevent enzymatic breakdown and substance loss.
Solution Approach 2:
The patent uses short truncated peptides (e.g., 7-8 amino acid sequences) that are inherently more stable and less susceptible to degradation than the full-length peptide. These shorter versions serve as effective, stable alternatives that reduce substance loss while maintaining therapeutic efficacy.
3Duration of action of moving object
If protease resistance is increased through mutation, then peptide stability is improved, but chemoattractant activity may be reduced
Solution Approach 1:
The patent applies local quality changes by making targeted modifications at specific amino acid positions (particularly the N-terminal region) while leaving the rest of the peptide structure intact. This localized approach allows protease resistance to be introduced without disrupting the critical regions responsible for chemoattractant activity.
Solution Approach 2:
The patent carefully adjusts amino acid sequence parameters at specific positions to achieve protease resistance while monitoring and preserving chemoattractant activity. This involves optimizing the balance between structural modification for stability and functional preservation for biological activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protease-resistant SDF-1 peptides effectively promote wound healing and tissue repair by maintaining chemoattractant activity and reducing susceptibility to enzymatic degradation, thereby improving tissue repair in conditions such as diabetic ulcers and myocardial infarction.
Implementation Method 1
protease-resistant mutants of stromal cell derived factor-1 (SDF-1)... renders them resistant to inactivation by proteases, particularly matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), dipeptidyl peptidase IV (DPPIV/CD26)
Data Source
AI summary
The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity.